News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cantargia’s Share Issue Of 20 MSEK Fully Subscribed


7/9/2014 1:58:14 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LUND, Sweden--(BUSINESS WIRE)--The completed share issue in Cantargia AB, directed to the shareholders in Lund University Bioscience AB, were fully subscribed. The share issue raises approximately 20 MSEK for Cantargia. Cantargia develops a unique pharmaceutical for leukemia, in which the cancer stem cells are killed and thereby eradicating the leukemia. The capital raised will enable Cantargia to start the final development steps for the drug, including toxicology, before initiating clinical trials.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Cantargia
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES